Molecular Sensing, Inc. is launching a breakthrough molecular interaction technology for drug discovery.
Back-Scattering Interferometry (BSI) enables:
Label-free, homogeneous interaction Kd measurements eliminating both bait molecule tethering and target molecule labeling.
|
Unprecedented sensitivity and Kd dynamic range for small molecule — large protein binding compared to SPR and ITC.
Analyze binding equilibrium Kd's from pM to mM in complex matrices — serum, DMSO, cell lysates, impure mixtures and cell membrane preparations.
Use of small quantities (nanomoles) and volumes (10 µL) of protein radically reducing target protein development and manufacturing cost.
| 
 |
Courtesy of Schrödinger, LLC
MSI is currently working toward commercial launch of the first BSI instrument for drug discovery and biomedical research. Immediate access to the technology is available through a service based Life-science Early Access Program (LEAP).
Please contact us if you have a critical need to improve:
Secondary screening
Lead optimization assay
Medicinal chemistry drug optimization
Biophysical profiling of drug candidate
|
Label free assays
- Inhibitor-target
- Protein-protein
- Ab-Ag
- Protein-DNA
- Membrane-ligand
|
Measurement of pM to mM Kd's
Assess promiscuous binders
Reduce protein target quantities
Correlation of cell-based assays to target binding assays
Binding studies in impure mixtures
|
|
